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Neurodegeneration caused by neuronal death 
occurs in different types of neurodegenerative 
diseases  and  leads  to  severe  morbidity  and 
mortality in humans. Glaucoma is a common 
optic neuropathy in which loss of retinal gan-
glion cells (RGCs) occurs because of apopto-
sis, resulting in loss of vision. Current treatment 
for glaucoma has only limited efficacy. Parkin-
son’s disease involves progressive death of do-
paminergic neurons in the brain and is the 
most common neurodegenerative movement 
disorder worldwide, with no satisfying cure 
currently. Ischemic stroke, in which cortical 
neurons die because of ischemia insult, repre-
sents  one  of  the  most  challenging  diseases   
clinically. Currently, thrombolytic therapy is 
the only available treatment and is limited to 
<10% of total stroke patients, with potentially 
deleterious  side  effects.  With  the  promise   
offered by the studies on Alzheimer’s disease 
(Reisberg et al., 2003; Lipton, 2006) and amy-
otrophic lateral sclerosis (Nirmalananthan and 
Greensmith, 2005), neuroprotection achieved 
by neuroprotective factors to enhance neuro-
nal survival has emerged to be a potentially 
promising  general  strategy  to  treat  different 
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Platelet-derived growth factor CC (PDGF-CC) is the third member of the PDGF family 
discovered after more than two decades of studies on the original members of the family, 
PDGF-AA and PDGF-BB. The biological function of PDGF-CC remains largely to be explored. 
We report a novel finding that PDGF-CC is a potent neuroprotective factor that acts by 
modulating glycogen synthase kinase 3 (GSK3) activity. In several different animal 
models of neuronal injury, such as axotomy-induced neuronal death, neurotoxin-induced 
neuronal injury, 6-hydroxydopamine–induced Parkinson’s dopaminergic neuronal death, and 
ischemia-induced stroke, PDGF-CC protein or gene delivery protected different types of 
neurons from apoptosis in both the retina and brain. On the other hand, loss-of-function 
assays using PDGF-C null mice, neutralizing antibody, or short hairpin RNA showed that 
PDGF-CC deficiency/inhibition exacerbated neuronal death in different neuronal tissues in 
vivo. Mechanistically, we revealed that the neuroprotective effect of PDGF-CC was achieved 
by regulating GSK3 phosphorylation and expression. Our data demonstrate that PDGF-CC 
is critically required for neuronal survival and may potentially be used to treat neurodegen-
erative diseases. Inhibition of the PDGF-CC–PDGF receptor pathway for different clinical 
purposes should be conducted with caution to preserve normal neuronal functions.
This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a   
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported 
license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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PDGF-C deficiency led to >40% fewer viable RGCs in the 
retina 2 wk after ONC injury (n = 9 or 11; P < 0.01; Fig. 1, 
F, G, and L). PDGF-C shRNA intravitreal injection, which 
decreased  PDGF-C  transcript  to  <50%  of  normal  level   
(n = 8; P < 0.01; Fig. 1 M), led to fewer viable RGCs in the 
retina compared with those of control group 2 wk after ONC 
injury (n = 7; P < 0.05; Fig. 1, H, I, and L). On the contrary, 
intravitreal injection of active rhPDGF-CC protein (500 ng/
eye; Li et al., 2000) increased the number of viable RGCs in 
the retina by 1.7-fold 2 wk after treatment (n = 8; P < 0.01; 
Fig. 1, J–L). Thus, both loss- and gain-of-function assays 
showed  that  PDGF-CC  is  critically  required  for  RGC   
survival after retina injury.
It is recently reported that intraventricular injection of 
PDGF-CC into normal mouse brain increased cerebrovascular 
permeability 1 h after injection (Su et al., 2008). We therefore 
tested whether PDGF-CC affected retinal permeability. First, 
PDGF-C deficiency did not affect Evan’s blue (EB) extravasa-
tion in the retina in PDGF-C null mice (n = 14–16; P > 0.05; 
Fig. 1 S). Second, intravitreal injection of PDGF-CC protein 
(500 ng/eye; Li et al., 2000) did not significantly affect retinal 
permeability at different time points tested even though intra-
vitreal injection of the same amount of BSA increased retinal 
permeability transiently (n = 8–10; P > 0.05; Fig. 1 T), con-
firming a negligible role of PDGF-CC in inducing retinal 
blood vessel permeability. Thus, PDGF-CC increased RGC 
survival without affecting retinal blood vessel permeability.
PDGF-CC regulates expression of apoptotic/cell death–related 
and survival/neurotrophic genes
We next performed a genome-wide gene expression profil-
ing assay using a whole mouse genome microarray to investi-
gate the molecular mechanisms underlying the neuroprotective 
effect of PDGF-CC. PDGF-CC treatment up- and down-
regulated the expression of numerous survival/neurotrophic 
and  apoptotic/cell  death–related  genes,  respectively,  in 
ONC-injured retinae (Tables I and II). Microarray data have 
been deposited in the Gene Expression Omnibus under   
accession no. GSE19207. We validated the microarray data 
using real-time PCR both in vivo and in vitro. PDGF-CC 
treatment (500 ng/eye) inhibited the expression of numerous 
apoptotic/cell death–related genes in ONC-injured retinae 
at different time points (n = 8; Fig. 1, N and O), and also in 
normal retinae (n = 8; Fig. 1 P). Further, PDGF-CC treatment 
up-regulated the expression of many neurotrophic/survival 
genes in the retinae with ONC (n = 8; Fig. 1, Q and R). The 
microarray  data  were  further  validated  in  other  types  of 
PDGF-CC–treated neuronal tissues or cells, including N-
methyl-D-aspartic acid (NMDA)–injured retinae (see Fig. 2, 
D and E), 6-hydroxydopamine (6-OHDA)–injured substan-
tia nigra (SN) in the brain (see Fig. 3, L and M), ischemia- 
injured brain cortex (see Fig. 4, G and I), and isolated primary 
cortex neurons (see Fig. 4 H). Thus, the neuroprotective   
effect of PDGF-CC is achieved, at least partially, by regulating 
the expression of numerous apoptotic/cell death–related and 
survival/neurotrophic genes in neuronal tissues.
types of neurodegenerative diseases (Schwartz, 2005). There-
fore, identifying such novel neuroprotective molecules is 
highly warranted.
Platelet-derived  growth  factor  CC  (PDGF-CC)  was   
discovered more than two decades after the initial studies on 
PDGF-AA and PDGF-BB as the third member of the PDGF 
family (Kazlauskas, 2000; Li et al., 2000; Heldin et al., 2002). 
The biological function of PDGF-CC remains largely to be 
explored.  PDGF-CC  protein  is  produced  as  a  secreted   
homodimer  that  needs  to  be  proteolytically  processed  to   
allow receptor binding (Li et al., 2000; Fredriksson et al., 
2005). PDGF-CC binds to and activates both PDGF recep-
tor  (PDGFR-) and PDGFR- (Li et al., 2000; Gilbertson 
et al., 2001; Li and Eriksson, 2003). PDGF-CC is critically 
required for embryonic development, as PDGF-CC defi-
ciency in mice led to postnatal lethality because of develop-
mental defects (Ding et al., 2004). In addition, the protein 
structure of PDGF-CC is predicted to be more similar to 
vascular endothelial growth factor than to the PDGFs, indi-
cating its potential functional uniqueness (Reigstad et al., 
2005). PDGF-CC is abundantly expressed in different types 
of neuronal tissues, including the brain (Ding et al., 2000; Li 
et al., 2000; Aase et al., 2002), eye (Aase et al., 2002; Lei et al., 
2007), and spinal cord (Hamada et al., 2000, 2002), indicat-
ing a role of PDGF-CC in the neural system. However,   
direct evidence has been lacking thus far.
In this study, we used several different animal models and 
approaches to investigate the neuronal effect of PDGF-CC. 
We also investigated the potential effect of PDGF-CC on 
blood  vessel  permeability  in  both  normal  and  pathological 
conditions in mouse retina and brain, because it was recently 
reported  that  intraventricular  injection  of  PDGF-CC  into 
normal  mouse  brain  increased  cerebrovascular  permeability 
(Rieckmann, 2008; Su et al., 2008). We found that PDGF-CC 
is a potent neuroprotective factor and rescued neurons from 
apoptosis in both injured retina and brain in vivo. We further 
revealed that the neuroprotective effect of PDGF-CC was 
achieved by regulating glycogen synthase kinase 3 (GSK3) 
phosphorylation. Thus, PDGF-CC is critically required for 
neuronal survival and may have a therapeutic value in treating 
neurodegenerative  diseases.  Suppression  of  the  PDGF–
PDGFR pathway for various therapeutic purposes should be 
conducted with caution to avoid neuronal damage.
RESULTS
PDGF-CC protects RGCs from axotomy-induced  
neuronal death
In situ hybridization detected  PDGF-C expression in the 
RGC layer and inner/outer nuclear layer (INL/ONL; Fig. 1 A) 
in the retina. Western blotting revealed PDGF-CC protein 
in the retina as several forms because of differential proteo-
lytic processing (Fig. 1 B). Real-time PCR revealed increased 
expression levels of PDGF-C and its receptors, PDGFR- 
and PDGFR-, in the retinae after optic nerve crush (ONC) 
injury (n = 6; P < 0.05 or 0.01; Fig. 1, C–E), indicating   
a potential role of PDGF-CC in injured retina. Indeed,   JEM VOL. 207, April 12, 2010 
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Figure 1.  PDGF-CC protects RGCs from axotomy-induced neuronal death. (A) In situ hybridization assay detected abundant PDGF-C expression in the 
retina mainly in the RGC layer and INL/ONL. Bar, 50 µm. (B) Western blot assay detected PDGF-CC expression in the retina as several forms because of differ-
ent proteolytic processing. (C–E) Real-time PCR showed up-regulated expression of PDGF-C, PDGFR-, and PDGFR-, in the retinae after ONC using -actin 
as an internal control (n = 6 eyes). (F, G, and L) PDGF-C deficiency led to fewer viable RGCs (blue) after ONC (n = 9 or 11 eyes). (H, I, L, and M) PDGF-C shRNA 
intravitreal injection decreased PDGF-C transcript level to <50% of normal level (M, n = 8 eyes) and led to fewer viable RGCs (blue) compared with that of the 
control group (H, I, and L, n = 7 eyes). (J–L) PDGF-CC protein intravitreal injection increased the number of viable RGCs (white) after ONC (n = 8 eyes).  
(N–P) Real-time PCR validated the genome-wide gene expression profiling data. PDGF-CC treatment down-regulated the expression of numerous apoptotic/cell 
death–related genes in retinae after ONC at different time points (N and O, n = 8 eyes) and in normal retina (P). (Q and R) PDGF-CC treatment up-regulated 
the expression of many neurotrophic/survival genes in ONC-injured retinae at different time points (n = 8 eyes). (S) No difference was found in EB extravasa-
tion in the retina between PDGF-C–deficient and wild-type mice (n = 14–16 eyes). (T) Intravitreal injection of PDGF-CC protein did not affect retinal perme-
ability at different time points, whereas the same amount of BSA increased retinal permeability transiently (n = 8–10 eyes). Bars: (F–K) 20 µm. *, P < 0.05;  
**, P < 0.01. The data are represented as means ± SEM of the number of determinations. All experiments were repeated independently once (A–E and M–R) or 
twice (F–L) with similar results. Representative images (A, B, and F–I) or pooled data (C–E and M–R) are shown. Ch, choroid; IS/OS, inner/outer segment.870 PDGF-CC protects neurons | Tang et al.
processing (Fig. 3 A). PDGF-C–deficient mice displayed fewer 
tyrosine hydroxylase (TH; a marker for dopaminergic neurons)–
positive cells in SN (Fig. 3 B) and fewer TH+ fibers in ST 
(Fig. 3 C) 7 d after 6-OHDA injury. Indeed, PDGF-C–deficient 
mice displayed an increased contralateral rotation rate (n = 9–15;   
P < 0.05; Fig. 3 D), indicating that PDGF-CC is required for 
dopaminergic neuron survival. PDGF-CC recombinant pro-
tein or gene delivery into SN (0.5 µg/SN) increased TH+ sig-
nals (dopaminergic neurons and axons) in both SN (n = 9–15; 
Fig. 3 E) and ST (n = 9–15; Fig. 3 F) in the 6-OHDA–injured 
mice measured by several different methods, including fluores-
cent staining (Fig. 3, E and F), real-time PCR (n = 6; P < 0.001 
or 0.01; Fig. 3 G), and Western blotting (n = 6; Fig. 3 J). On 
the contrary, PDGF-C shRNA treatment, which decreased   
the PDGF-C expression level to <50% of normal (n = 8; P <   
0.01; Fig. S1 A), decreased the TH expression level in   
the  6-OHDA–injured  SN  measured  by  real-time  PCR   
(n = 6; P < 0.05; Fig. 3 G) and Western blotting (n = 6;   
Fig. 3 K). Moreover, PDGF-CC protein and gene delivery 
also increased expression level of c-fos (an inducible tran-
scription factor used to determine neuron activation in re-
sponse to dopaminomimetic compounds; Zhang et al., 2006) 
in 6-OHDA–injured SN, whereas PDGF-C shRNA treat-
ment decreased c-fos expression (n = 6; P < 0.01; Fig. 3 H). 
Functionally,  PDGF-CC  protein  or  gene  delivery  into  SN 
decreased the contralateral turning rate of the 6-OHDA– 
injured mice 2 wk after treatment (n = 9 or 15; P < 0.01; Fig. 3 I).   
PDGF-CC  overexpression  in  SN  after  gene  delivery  was 
confirmed by fluorescent staining (Fig. S1 B). EB extravasa-
tion assay showed that PDGF-CC protein SN injection did 
not change blood vessel permeability in SN at different time 
points (n = 8; P > 0.05; Fig. S1 C). At the gene expression 
level, PDGF-CC treatment down- and up-regulated the ex-
pression of numerous apoptotic/cell death–related (Fig. 3 L)   
and  neurotrophic/survival  genes  (Fig.  3  M),  respectively, 
in  the  6-OHDA–injured  SN.  Thus,  both  loss-  and  gain- 
of-function assays showed that PDGF-CC is required for the 
survival of dopaminergic neurons in the brain.
PDGF-CC protects neurons from neurotoxin-induced apoptosis
Overstimulation of the NMDA receptor by glutamate leading 
to neuronal apoptosis is implicated in many neurodegenera-
tive disorders. We therefore tested whether PDGF-CC could 
inhibit NMDA-induced apoptosis in mouse retina. Because 
NMDA induces only neuronal apoptosis without affecting the 
vascular system and PDGF-CC treatment in this model lasts only 
for 24 h (a time window too short for new blood vessels to 
grow), this model thus allowed us to verify the neuronal effect 
of  PDGF-CC  without  implicating  the  vascular  system.  We 
injected NMDA (20 nmol/eye) with or without PDGF-CC 
protein (500 ng/eye) intravitreally into mouse eyes and analyzed 
apoptosis in the retina after 24 h. PDGF-CC protein treatment 
reduced the number of apoptotic cells in the RGC layer and 
INL/ONL (n = 8; P < 0.01 or 0.05; Fig. 2, A–C). Further, 
real-time PCR detected up- and down-regulated expression   
of many neurotrophic/survival (n = 8; Fig. 2 D) and apo-
ptotic/cell death–related genes (n = 8; Fig. 2 E), respectively, 
in the NMDA-injured retina after PDGF-CC treatment. Thus, 
PDGF-CC protected NMDA excitotoxin-injured retinal neu-
rons, at least partially, by regulating the expression of many 
neurotrophic/survival and apoptotic/cell death–related genes.
PDGF-CC protects dopaminergic neurons from apoptosis in SN
We next tested whether PDGF-CC affects dopaminergic 
neuron survival in the brain using a 6-OHDA–induced Par-
kinson’s disease model. Western blotting detected PDGF-CC 
protein in both SN (where dopaminergic neurons reside) 
and striatum (ST; where the axons of dopaminergic neu-
rons reside) as several forms because of different proteolytic   
Table I.  Survival/antiapoptotic genes up-regulated  
by PDGF-CC
Gene name Accession no. Fold up-regulated
SGK1 NM_011361 3.3
PEA15 NM_011063.1 2.2
DCTN1 NM_007835.1 2.2
UBQLN1 NM_152234.1 1.9
API5 NM_007466 1.9
RAF1 AK036317 1.7
UNC5C NM_009472.1 1.7
SMPD1 NM_011421.1 1.7
SKP2 AK037002 1.7
MDM4 NM_008575.2 1.7
HIPK3 NM_010434.1 1.6
TAF10 NM_020024.3 1.5
FKBP8 NM_010223.1 1.5
EIF5A NM_181582.2 1.5
PDE1B NM_008800.1 1.5
MAPK8 AK030767 1.5
CNTF NM_170786 1.5
NGFR NM_033217 1.5
Nucleotide sequences are available from GenBank/EMBL/DDBJ under the accession 
numbers listed.
Table II.  Apoptotic/cell death–related genes down-regulated 
by PDGF-CC
Gene name Accession no. Fold down-regulated
TRAF7 NM_153792.1 1.9
FAIM NM_011810.2 1.7
EEF1E1 NM_025380.1 1.6
UACA NM_028283 1.6
AATK NM_007377.1 1.6
NFKBIA NM_010907 1.5
DIABLO NM_023232.2 1.5
PDCD4 NM_011050.1 1.5
BAX NM_007527.2 1.5
GAL NM_010253 1.5
Nucleotide sequences are available from GenBank/EMBL/DDBJ under the accession 
numbers listed.JEM VOL. 207, April 12, 2010 
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brains (n = 10; P = 0.4; Fig. 4 J) or brains with MCAO- 
induced ischemia (n = 8; P = 0.3; Fig. 4 K), suggesting a 
negligible role of PDGF-CC in inducing blood vessel per-
meability in the brain. Indeed, PDGF-CC protein CSF   
injection (3 µl × 3 µM/mouse) did not increase blood vessel 
permeability 1 h after injection in normal brain (n = 8; Fig. 4 L) 
or in brains with MCAO-induced ischemia (n = 8; Fig. 4 M).
Direct protective effect of PDGF-CC on cultured neurons
We cultured different types of neuronal cells derived from 
retina or brain to investigate whether PDGF-CC has a direct 
neuroprotective effect on them. We treated RGC5 cells (an 
RGC-derived cell line) with H2O2, which is known to   
induce oxidative stress–induced apoptosis. PDGF-CC treat-
ment  (50  ng/ml)  significantly  decreased  H2O2-induced 
apoptosis in RGC5 cells and increased their survival at dif-
ferent time points tested (n = 6; P < 0.05; Fig. 5, A–C). 
 PDGF-CC treatment (50 ng/ml) also increased the survival 
of primary retinal neuroprogenitor cells isolated from post-
natal  day  1  (P1)  mice  cultured  in  serum-free  medium   
using islet1+ as a marker (n = 6; P < 0.01; Fig. 5, D–F). 
Further,  PDGF-CC  treatment  decreased  hypoxia-  and 
glucose deprivation–induced apoptosis in primary cortical 
neurons isolated from P1 mice by >50% (n = 6; P < 0.01; 
Fig. 5, G–I). Moreover, PDGF-CC treatment (50 ng/ml) 
increased survival of primary TH+ neurons isolated from 
E13.5 mouse embryonic SNs when the neurons were cul-
tured in serum-free medium (n = 6; P < 0.001; Fig. 5, J–L), 
or stressed by neurotoxin 6-OHDA treatment (n = 6; P < 
0.05 or 0.01; Fig. 5, M–O). Thus, PDGF-CC displayed a 
direct neuroprotective effect on different types of neurons 
in culture.
PDGF-CC protects cortical neurons from ischemia-induced 
neuronal death
We next tested whether PDGF-CC could rescue ischemia-
induced cortex neuronal death using a middle cerebral artery 
occlusion (MCAO) stroke mouse model. Western blotting 
detected  abundant  PDGF-CC  expression  in  brain  cortex 
(Fig. 4 A), indicating a potential role of PDGF-CC in the 
brain. We injected active PDGF-CC protein (Li et al., 2000) 
or a PDGF-CC neutralizing antibody into mouse cerebrospi-
nal fluid (CSF; 3 µl × 3 µM/mouse), performed MCAO 1 h 
after protein injection, and measured stroke volume after 24 h. 
PDGF-CC protein CSF injection decreased stroke volume 
(n = 11 or 13; P < 0.05; Fig. 4, B and C), whereas CSF injec-
tion of a neutralizing antibody against mouse PDGF-CC en-
larged stroke volume (n = 9 or 11; P < 0.05; Fig. 4 C). 
Moreover, PDGF-CC protein cortex injection (0.15 µg/ 
0.5 µl × three sites) decreased stroke volume by 76% 7 d after 
protein injection (n = 10; P < 0.05; Fig. 4, D and E). Loss-
of-function  assay  using  PDGF-C  null  mice  showed  that 
PDGF-C deficiency led to significantly greater stroke volume 
(n = 8; P < 0.01; Fig. 4 F), further demonstrating a critical 
role of PDGF-CC in cortex neuron survival. Real-time PCR 
revealed increased expression of many neurotrophic/survival 
factors in both brain cortex (n = 6; Fig. 4 G) and isolated pri-
mary cortical neurons (n = 4; Fig. 4 H) after PDGF-CC treat-
ment, and decreased expression of numerous apoptotic/cell 
death–related genes (n = 8; Fig. 4 I). Thus, PDGF-CC is 
critically required for cortex neuron survival in the brain.
Using PDGF-C–deficient mice as a genetic tool to test 
whether PDGF-CC affects cerebrovascular permeability, no 
significant difference in EB extravasation was found between 
PDGF-C–deficient  and  wild-type  mice  in  either  normal 
Figure 2.  PDGF-CC inhibits NMDA-induced neuronal apoptosis in retina. (A–C) PDGF-CC treatment reduced the number of apoptotic cells (red) in 
the RGC layer and INL/ONL after NMDA injury measured by TUNEL staining (n = 8 eyes). Bar, 20 µm. (D and E) Real-time PCR revealed that PDGF-CC 
treatment up-regulated the expression of several neurotrophic/survival genes (D) and inhibited the expression of numerous apoptotic/cell death–related 
genes in the NMDA-injured retina (E; n = 8 eyes). *, P < 0.05; **, P < 0.01. The data are represented as means ± SEM of the number of determinations. All 
experiments were repeated independently once with similar results. Representative images (A and B) or pooled data (D and E) are shown.872 PDGF-CC protects neurons | Tang et al.
Figure 3.  PDGF-CC protects dopaminergic neurons from apoptosis. (A) Western blotting detected PDGF-CC expression in the SN and ST in the 
brain as several forms because of differential proteolytic processing. (B and C) PDGF-C deficiency led to fewer TH+ cells in SN (B) and fewer TH+ fibers in 
ST (C) in the lesion side of the brain 7 d after 6-OHDA injury. The images shown in C represent a mosaic of several individual images. (D) PDGF-C–deficient 
mice displayed an increased contralateral rotation rate 1 wk after 6-OHDA injury (n = 9 or 15 mice). (E and F) PDGF-CC protein SN injection increased TH+ 
signals (dopaminergic neurons) in both SN (E) and ST (F) in 6-OHDA–injured brain measured by immunofluorescent staining (n = 9 or 15 mice). (G and H) 
PDGF-CC protein treatment increased expression levels of TH (G) and c-fos (H) in SN, whereas PDGF-C shRNA treatment decreased their expression levels 
(G and H) measured by real-time PCR. PDGF-C gene delivery (PDGF-C plasmid) into SN increased TH and c-fos expression levels (n = 6 mice). (I) PDGF-CC 
protein or gene delivery into SN decreased contralateral turning rate in the 6-OHDA–injured mice at different time points (n = 9 or 15 mice). (J) PDGF-C 
plasmid gene delivery (PDGF-C pls) increased TH expression level in both SN and ST at different time points measured by Western blotting (n = 6 mice). 
(K) PDGF-C shRNA treatment decreased TH expression level in both SN and ST in 6-OHDA–injured SN at different time points measured by Western blot-
ting (n = 6 mice). (L) PDGF-CC protein treatment inhibited expression of numerous apoptotic/cell death–related genes in 6-OHDA–injured SN at different 
time points measured by real-time PCR. (M) PDGF-CC protein treatment up-regulated expression of many neurotrophic/survival factors in 6-OHDA– 
injured SN at different time points measured by real-time PCR. Bars: (B and E) 200 µm; (C and F) 400 µm. *, P < 0.05; **, P < 0.01; ***, P < 0.001. The data 
are represented as means ± SEM of the number of determinations. All experiments were repeated independently once (A, G, H, and J–M) or twice (B–F 
and I) with similar results. Representative images (A–C, E, F, J, and K) or pooled data (G–I, L, and M) are shown.JEM VOL. 207, April 12, 2010 
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Both PDGFR- and PDGFR- mediate the neuroprotective 
effect of PDGF-CC
PDGF-CC binds to and activates PDGFR- and PDGFR- 
(Li et al., 2000; Gilbertson et al., 2001; Cao et al., 2002; Li 
and Eriksson, 2003). Real-time PCR detected PDGFR- 
and PDGFR- expression in both the retina (Fig. 6 A) and 
primary cortical neurons (Fig. 6 B). PDGF-CC protein treat-
ment  up-regulated  PDGFR-  and  PDGFR-  expression 
(Fig. 6 B). Immunoprecipitation followed by immunoblotting 
assay showed that PDGF-CC stimulation led to PDGFR-   
and PDGFR- activation in different types of neuronal cells 
and tissues, including RGC5 cells, primary cortical neurons, 
and SN (Fig. 6, C and D). Immunofluorescent staining using 
antibodies against phosphorylated PDGFR- or PDGFR- 
detected activated PDGFR- and PDGFR- mainly in the 
RGC layer in the retina after PDGF-CC (500 ng/eye) intra-
vitreal injection (Fig. 6 E), and also in Map2+ (neuronal 
marker)  primary  cortical  neurons  after  PDGF-CC  protein 
treatment (Fig. S1, D and E). In cultured primary cortical 
neurons, PDGF-CC protein treatment (50 ng/ml) inhibited 
the expression of several proapoptotic genes (n = 6; P < 0.01; 
Fig. 6 F), and up-regulated the expression of many neurotrophic/
Figure 4.  PDGF-CC protects brain cortical neurons from ischemia-induced neuronal death. (A) Western blotting detected PDGF-CC expression in 
brain cortex as several forms because of differential proteolytic processing. (B and C) PDGF-CC protein CSF injection decreased stroke volume, whereas 
CSF injection of PDGF-CC neutralizing antibody (anti–PDGF-CC) enlarged stroke volume (n = 11 or 13 mice). (D and E) PDGF-CC protein pretreatment by 
cortex injection decreased stroke volume significantly (n = 10 mice). (F) PDGF-C–deficient mice displayed greater stroke volume than that of wild-type 
mice (n = 8 mice). (G and H) Real-time PCR showed up-regulated expression of many neurotrophic/survival factors in brain cortex (G, n = 6 mice) and in 
isolated primary cortical neurons (H, n = 4 mice) after PDGF-CC treatment. (I) PDGF-CC treatment inhibited the expression of numerous apoptotic/cell 
death–related genes in brain cortex (n = 8 mice). (J and K) No difference in EB extravasation was found between PDGF-C–deficient and wild-type mice in 
normal brains (J, n = 10 mice) or brains with MCAO (K). (L and M) PDGF-CC CSF injection did not increase blood vessel permeability in normal brain (L, n = 
8 mice) or in brains with MCAO (M, n = 8 mice). *, P < 0.05; **, P < 0.01. The data are represented as means ± SEM of the number of determinations. All 
experiments were repeated independently one to three times with similar results. Representative images (A, B, and D) and experiments are shown.874 PDGF-CC protects neurons | Tang et al.
to significant Akt activation in cultured RGC5 cells (Fig. 7 A). 
Thus, the neuroprotective effect of PDGF-CC is mediated by 
both PDGFR- and PDGFR-.
PDGF-CC induces and inhibits GSK3 Ser9 and Tyr216 
phosphorylation, respectively
To further investigate the intracellular signaling pathways   
induced by PDGF-CC, we screened a phospho–mitogen- 
activated protein kinase (MAPK) array to pinpoint the down-
survival genes (n = 6; P < 0.05, 0.01, or 0.001; Fig. 6 G). 
However, this regulatory effect of PDGF-CC on gene ex-
pression in cortical neurons was largely abolished by both 
PDGFR-  and  PDGFR-  neutralizing  antibodies   
(n = 6; P < 0.05, 0.01, or 0.001; Fig. 6, F and G). Function-
ally, PDGFR- or PDGFR- neutralizing antibody treat-
ment largely abolished the survival effect of PDGF-CC on 
RGCs in the ONC injury model in vivo (n = 8; P < 0.01; 
Fig. 6, H and I). In addition, PDGF-CC protein treatment led 
Figure 5.  Direct protective effect of PDGF-CC on cultured neurons. (A–C) PDGF-CC treatment significantly decreased H2O2-induced apoptosis of the 
RGC5 cells measured by TUNEL staining (green; A and B) and increased their survival when the cells were cultured in serum-free medium (C). (D–F) PDGF-CC 
treatment increased survival of retinal neural progenitor cells (islet1+; red) when cultured in serum-free medium. (G–I) PDGF-CC treatment decreased hypoxia- 
and glucose deprivation–induced apoptosis in primary cortical neurons measured by TUNEL staining (green). (J–L) PDGF-CC treatment increased survival of TH+ 
neurons cultured in serum-free medium measured by TH staining (red). (M–O) PDGF-CC treatment increased survival of TH+ neurons measured by TH staining 
(red) when the neurons were stressed with neurotoxin 6-OHDA. Bars, 10 µm. *, P < 0.05; **, P < 0.01; ***, P < 0.001. The data are represented as means ± SEM of 
the number of determinations. All experiments were repeated independently twice with similar results. Representative images and experiments are shown.JEM VOL. 207, April 12, 2010 
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vein smooth muscle cells (HUVSMCs; Fig. 7 B, top, arrows). 
It is known that GSK3 plays important roles in neuronal 
apoptosis (Liang and Chuang, 2007). GSK3 phosphorylation 
stream effectors. Out of many signaling molecules screened, 
PDGF-CC protein treatment (50 ng/ml for 10 min) increased 
GSK3 Ser9 phosphorylation specifically in human umbilical 
Figure 6.  Both PDGFR- and PDGFR- mediate the neuroprotective effect of PDGF-CC. (A) PDGFR- and PDGFR- were expressed in the  
retina, with the PDGFR- expression level being more abundant as measured by real-time PCR. (B) Real-time PCR detected PDGFR- and PDGFR-  
expression at a similar level in primary cortical neurons. PDGF-CC protein up-regulated their expression. (C and D) Immunoprecipitation followed by im-
munoblotting (antiphosphotyrosine antibody [anti-pTyr]) detected PDGFR- (C) and PDGFR- (D) activation by PDGF-CC in RGC5 cells, primary cortical 
neurons, and SN using total PDGFR-/ as controls (anti–tPDGFR-/). (E) Immunofluorescent staining using antibodies against phosphorylated PDGFR-  
and PDGFR- detected activated PDGFR- and PDGFR- (green) mainly in the RGC layer in the retina after PDGF-CC treatment. Bar, 50 µm. (F) PDGF-CC 
treatment inhibited expression of several proapoptotic genes in cortical neurons. The effect of PDGF-CC was largely abolished by both PDGFR- and 
PDGFR- neutralizing antibodies (n = 6 mice). (G) PDGF-CC treatment up-regulated the expression of many neurotrophic/survival genes in cortical neu-
rons. This effect of PDGF-CC was abolished by both PDGFR- and PDGFR- neutralizing antibodies (n = 6 mice). (H and I) In the ONC model, both 
PDGFR- and PDGFR- neutralizing antibodies abolished the survival effect of PDGF-CC on RGCs (white; n = 8 eyes). Bar, 20 µm. *, P < 0.05; **, P < 0.01; 
***, P < 0.001. The data are represented as means ± SEM of the number of determinations. All experiments were repeated independently once (A, B, and 
E–G) or twice (C, D, H, and I) with similar results. Representative images (C–E and I) and experiments are shown. IB, immunoblotting; IP, immunoprecipita-
tion; IPL, inner plexiform layer; IS/OS, inner/outer segment; nab, neutralizing antibody.876 PDGF-CC protects neurons | Tang et al.
Figure 7.  Neuroprotective effect of PDGF-CC is achieved by regulating GSK3 phosphorylation. (A) PDGF-CC protein treatment activated Akt 
significantly in cultured RGC5 cells. (B) In a phospho-MAPK array screening assay, PDGF-CC treatment increased GSK3 Ser9 phosphorylation specifically 
(top, arrows) in HUVSMCs, whereas the phosphorylation of the other molecules remained unchanged. (C and D) In cultured PC12 (C) and RGC5 (D)  
neuronal cells, PDGF-CC protein treatment increased GSK3 Ser9 phosphorylation and decreased GSK3 Tyr216 phosphorylation, respectively, in a time-
dependent manner. Black lines indicate that intervening lanes have been spliced out. (E and F) PDGF-CC protein treatment increased GSK3 Ser9 phos-
phorylation (E) and decreased GSK3 Tyr216 phosphorylation (F), respectively, in the retina in vivo. (G) PDGF-CC neutralizing antibody treatment increased 
GSK3 Tyr216 phosphorylation in the retina in vivo. (H) PDGF-CC protein treatment inhibited GSK3 expression in different types of neuronal tissues/cells, 
including SN, retina (normal or with ONC/NMDA injury), RGC5 cells, and brain cortex with MCAO as measured by real-time PCR. (I) PDGF-CC protein 
treatment protected RGC5 cells from H2O2-induced cell death in the control cells and cells expressing wild-type GSK3 (GSK3-WT). The protective effect 
of PDGF-CC diminished in the RGC5 cells expressing mutant GSK3, in which Ser9 was mutated to alanine (GSK3-A9). **, P < 0.01; ***, P < 0.001. The 
data are represented as means ± SEM of the number of determinations. Experiments, except B, were repeated independently twice with similar results. 
Representative images (A and C–G) and experiments are shown. nab, neutralizing antibody.
at Ser9 inhibits its apoptotic activity, whereas phosphorylation 
at Tyr216 promotes its apoptotic activity (Liang and Chuang, 
2007). We validated the phospho-MAPK screening data both 
in vitro and in vivo. In cultured PC12 and RGC5 neuronal 
cells,  PDGF-CC  protein  stimulation  led  to  GSK3  Ser9 
phosphorylation and GSK3 Tyr216 dephosphorylation, re-
spectively, in a time-dependent manner (Fig. 7, C and D). 
This observation was confirmed in vivo. PDGF-CC protein 
intravitreal injection (500 ng/eye) increased Ser9 phosphory-
lation (Fig. 7 E) and decreased Tyr216 phosphorylation (Fig. 7 F) 
in the retina, respectively, both of which are known to inhibit 
the apoptotic activity of GSK3 (Liang and Chuang, 2007). 
On the contrary, loss-of-function assay showed that PDGF-CC 
neutralizing antibody intravitreal injection led to increased 
GSK3 Tyr216 phosphorylation in the retina (increasing the 
apoptotic activity of GSK3; Fig. 7 G). Further, PDGF-CC 
protein treatment also down-regulated GSK3 expression in 
different types of neuronal tissues, including SN, retina   
(normal or with ONC/NMDA injury), RGC5 cells, and 
brain cortex with MCAO-induced ischemia, as measured 
by real-time PCR (Fig. 7 H).
To further verify whether the neuroprotective effect of 
PDGF-CC was achieved by inducing GSK3 Ser9 phos-
phorylation, we expressed the wild-type or mutant human 
GSK3, in which Ser9 was mutated to alanine (GSK3-WT 
or GSK3-A9, respectively; Stambolic and Woodgett, 1994) 
in RGC5 cells. PDGF-CC protein treatment protected the 
RGC5 cells from H2O2-induced cell death in the control 
cells as well as in cells expressing GSK3-WT (n = 6;   
P < 0.001 or 0.01; Fig. 7 I). However, the protective effect JEM VOL. 207, April 12, 2010 
Article
877
are expressed (Lee et al., 2004). Accumulating data have 
thus indicated a potential role of PDGF-CC in the neural 
system. However, direct evidence has been lacking thus far. 
In this study, we found that PDGF-CC was highly expressed 
in both retina and brain. PDGF-C deficiency by genetic 
gene deletion or shRNA gene knocking down exacerbated 
neuronal death in both retina and brain under pathological 
conditions. On the contrary, PDGF-CC protein treatment 
or gene delivery protected both retinal and brain neurons 
from apoptosis in different pathological conditions in vivo. 
It is worth noting that the neuroprotective effect of PDGF-CC 
is on several different types of neurons in different tissues, 
including RGCs, neuronal cells in the INL/ONL in the 
retina, dopaminergic neurons in SN, and brain cortical   
neurons. Thus, PDGF-CC is a broad-acting neuroprotec-
tive factor for different types of neurons. Further studies on 
the therapeutic potential of PDGF-CC protein, gene, and 
cell therapy to treat different types of neurodegenerative 
diseases are therefore warranted.
In this study, we found that both PDGFR- and PDGFR- 
are expressed in different types of neurons. PDGF-CC pro-
tein stimulation activated both PDGFR- and PDGFR- in 
the retina and brain in vivo, and in cultured neuronal cells 
in vitro. Furthermore, PDGFR- and PDGFR- neutralizing 
antibodies largely abolished the neuroprotective effect of 
PDGF-CC on RGCs in vivo and the regulatory effect of 
PDGF-CC on gene expression in vitro. Thus, the neuropro-
tective effect of PDGF-CC was mediated by both PDGFR- 
and PDGFR-. We further explored the intracellular signal-
ing pathway induced by PDGF-CC. Using a phospho-MAPK 
array, we found that out of numerous different signaling mol-
ecules screened, PDGF-CC specifically induced GSK3 Ser9 
phosphorylation. It is known that GSK3 is a proapoptotic 
gene playing important roles in neuronal apoptosis (Liang and 
Chuang, 2007). GSK3 phosphorylation at Ser9 inhibits its 
apoptotic activity, whereas phosphorylation at Tyr216 pro-
motes its apoptotic activity (Liang and Chuang, 2007). In-
deed, we validated the phospho-MAPK screening data both 
in vitro and in vivo. In cultured neuronal cells and in mouse 
retinae, PDGF-CC protein stimulation increased and de-
creased  GSK3  Ser9  and  GSK3  Tyr216  phosphorylation,   
respectively, indicating that the neuroprotective effect of 
PDGF-CC was achieved by regulating GSK3 phosphoryla-
tion. Indeed, this observation was confirmed by a loss- 
of-function assay. When the GSK3 Ser9 was mutated to an 
alanine and the mutant GSK3-A9 was expressed in RGC5 
cells, the protective effect of PDGF-CC on RGC5 cells was 
abolished, whereas PDGF-CC protected the RGC5 cells 
expressing  GSK3-WT  from  H2O2-induced  cell  death,   
demonstrating that the neuroprotective effect of PDGF-CC 
was achieved by regulating GSK3 phosphorylation.
It was recently reported that intraventricular injection of 
PDGF-CC protein increased cerebrovascular permeability in 
normal mice (Su et al., 2008). It was therefore hypothesized 
that blocking the PDGFR–PDGF-CC pathway may extend 
the therapeutic time window of tissue plasminogen activator, 
of PDGF-CC diminished in the cells expressing GSK3-A9 
(lacking Ser9 phosphorylation; n = 6; Fig. 7 I), demonstrating 
that PDGF-CC–induced GSK3 Ser9 phosphorylation was 
required for its neuroprotective effect.
PDGF-CC at a dose effective for neuroprotection did not 
induce angiogenesis
Our previous work showed that PDGF-CC at a higher dose 
(4.5 µg/mouse/day × 7 d) promoted angiogenesis in patholog-
ical conditions in the heart (Dimmeler, 2005; Li et al., 2005). 
We therefore investigated whether PDGF-CC protein treat-
ment at a dose effective for neuroprotection induced angiogen-
esis in neuronal tissues. CD31 (endothelial cell marker) and 
smooth muscle cell -actin (smooth muscle cell marker) stain-
ing showed that 7 d after cortex injection of PDGF-CC pro-
tein (0.15 µg/0.5 µl PBS × three sites), there was no difference 
in blood vessel density in the stroke zone or the border zone 
surrounding the stroke region between PDGF-CC– and BSA-
treated samples (n = 5; P > 0.05; Fig. S2, A–C). In the SN   
region, 2 wk after PDGF-CC protein injection (500 ng/SN), 
no  difference  in  blood  vessel  density  was  found  between 
PDGF-CC– and BSA-treated SN samples measured by CD31 
staining (n = 5; P > 0.05; Fig. S2, D and E). Similarly, in the 
retina, 2 wk after PDGF-CC protein injection (500 ng/eye), 
no  difference  in  blood  vessel  density  was  found  between 
PDGF-CC– and BSA-treated retinae measured by collagen IV 
staining (n = 6; P > 0.05; Fig. S2, F–H). Thus, PDGF-CC at a 
dose effective for neuroprotection did not induce angiogenesis.
DISCUSSION
The PDGF family is best known as mitogens and chemoat-
tractants for various types of mesenchyme cells, and for their 
critical roles during development (Andrae et al., 2008). 
However, their neuronal effects have been less explored.   
In this study, using several neuronal injury animal models 
and loss- and gain-of-function assays, we showed, for the 
first time to our knowledge, that PDGF-CC is a potent 
neuroprotective factor for various types of neurons by regu-
lating GSK3 phosphorylation. PDGF-CC treatment res-
cued  both  retina  and  brain  neurons  from  apoptosis  in 
different  animal  models  in  vivo,  and  inhibited  oxidative 
stress–, neurotoxin-, and serum deprivation–induced neu-
ronal apoptosis in vitro. We further revealed a novel molec-
ular  mechanism  underlying  the  neuroprotective  effect  of 
PDGF-CC. Both in vitro and in vivo, PDGF-CC treatment 
increased and decreased GSK3 Ser9 and Tyr216 phosphory-
lation, respectively. Thus, because of its potent neuroprotective 
effect, PDGF-CC may potentially be used to treat neuro-
degenerative diseases. Suppression of the PDGF–PDGFR 
pathway for different clinical purposes should be conducted 
with caution to maintain normal neuronal function.
PDGF-CC is abundantly expressed in different types of 
neural tissues, including the brain, spinal cord, cochlea, etc. 
(Li et al., 2000; Aase et al., 2002; Hamada et al., 2002; Lee 
et al., 2004; Lei and Kazlauskas, 2008). In the inner ear   
neuronal cells, PDGF-CC and PDGF-AA, but not PDGF-BB, 878 PDGF-CC protects neurons | Tang et al.
In summary, using different techniques and approaches, 
we showed, for the first time to our knowledge, that PDGF-CC 
is a potent neuroprotective factor and is critical for neuronal 
survival. We further revealed a novel molecular mechanism 
underlying the neuroprotective effect of PDGF-CC. That is, 
PDGF-CC achieves its neuroprotective effect by regulating 
GSK3 phosphorylation. Thus, PDGF-CC may have thera-
peutic values in treating neurodegenerative diseases. Interfer-
ence  of  the  PDGFR  pathway  for  different  therapeutic 
purposes should be conducted with caution.
MATERIALS AND METHODS
ONC and NMDA retina injury models. All animal experiments were ap-
proved by the Animal Care and Use Committee at the National Eye Institute, 
National Institutes of Health (NIH; animal study protocols 06-553, 06-570, and 
07-608), and were performed according to NIH guidelines and regulations on 
animal studies. The ONC and NMDA retinal injury models were performed 
and results were analyzed as described previously (Li et al., 2008). PDGF-C–
deficient mice were described previously (Ding et al., 2004) and were bred onto 
a C57BL/6 background for more than six generations, and littermates were 
used for experiments. For PDGF-CC protein or shRNA treatment in the 
ONC injury model, 0.5 µg/µl × 1 µl of active rhPDGF-CC protein (Li et al., 
2000) or shRNA (1 µg/eye; Open Biosystems) was injected into mouse vitre-
ous once a week for 2 wk. In the NMDA injury model, 0.5 µg/µl × 1 µl of 
PDGF-CC protein was injected into mouse vitreous. For PDGFR blocking as-
say, PDGFR- or PDGFR- neutralizing antibody (5 µg/eye; R&D Systems) 
was injected into mouse vitreous once a week for 2 wk.
Permeability assay. EB extravasation permeability assay in different tissues 
was performed as previously described (Su et al., 2008). For brain permeabil-
ity assay, anesthetized C57BL/6 mice were placed onto a stereotactic frame. 
Active rhPDGF-CC core domain protein (3 µl of 3 µM; Li et al., 2000) or 
the  same  amount  of  BSA  was  intraventricularly  injected  into  CSF  at  a   
position of bregma 2 mm, mediolateral 0 mm, and dorsoventral 2 mm. 
Cerebrovascular  permeability  was  determined  at  different  time  points  as   
previously described (Su et al., 2008). In brief, mice were intravenously in-
jected with 100 µl of 4% EB (Sigma-Aldrich) at different time points after 
MCAO. 1 h after EB injection, animals were perfused with PBS for 4 min, 
and brains were removed and separated into hemispheres ipsilateral and con-
tralateral to the MCAO. Each hemisphere was then homogenized in N,N-
dimethylformamide (Sigma-Aldrich), and EB extravasation was measured as 
previously described (Su et al., 2008). For retina permeability assay, active 
rhPDGF-CC protein (500 ng/eye; Li et al., 2000) or the same amount of 
BSA was injected into mouse vitreous, and retina permeability was measured 
at different time points as previously described (Su et al., 2008).
Parkinson’s disease model. The neurotoxin-induced Parkinson’s disease 
model was performed using 8–10-wk-old female mice as described previ-
ously with some modifications (Lindholm et al., 2007). 2 µl 6-OHDA   
(4 µg/µl in 0.2 mg/ml ascorbate-saline; Sigma-Aldrich) was injected into 
the right medial forebrain bundle at 1.9 mm posterior to the bregma, 1 mm 
lateral to the midline, and 4.4 mm below the dura. 1–3 wk after 6-OHDA 
injection, mice received intraperitoneal injection of D-apomorphine (0.05 
mg/kg) and were allowed to habituate in a box with a flat round bottom 
(24 cm in diameter) for 5 min, and the contralateral turning was counted 
during the following 2 min. To test the effect of PDGF-CC, PDGF-CC 
protein or BSA control (500 ng/mouse) was injected into the right SN at 
3.3 mm posterior to the bregma, 1.35 mm lateral to the midline, and   
4.4 mm below the dura 30 min before 6-OHDA injection. For PDGF-C 
gene or shRNA delivery, a PDGF-C expression construct (PDGF-CC core   
domain cloned into a pLenti-6/V5 vector; Invitrogen) or shRNA (2 µg of 
plasmid in 0.5 µl PBS) together with the in vivo transfection reagent (Jet-
PEI; Polyplus-transfection) were injected into SN 1 wk before 6-OHDA 
injection. Brains were harvested at different time points (3 d to 3 wk after 
which can activate the latent form of PDGF-CC (Fredriksson 
et al., 2004; Rieckmann, 2008; Su et al., 2008). This study 
(Su et al., 2008) is of significant importance as it may lead to 
a therapeutic breakthrough in stroke treatment. Based on this 
study, a clinical trial was planned to treat stroke patients with 
imatinib (Gleevec) to block the PDGFR pathways (Rieckmann, 
2008; Su et al., 2008). In our current study, using PDGF-C–
deficient mice as a genetic tool, no difference in EB extrava-
sation was found between PDGF-C–deficient and wild-type 
mice in the retinae, normal brains, or brains with MCAO-
induced ischemia, suggesting that PDGF-CC has a negligible 
role in inducing blood vessel permeability in these tissues. In 
support of this, PDGF-CC protein injection into vitreous, 
SN, normal brain, or brain with MCAO-induced ischemia 
did not change EB extravasation in the eye or brain. Instead, 
PDGF-CC  protein  or  gene  delivery  into  these  tissues   
decreased neuronal death in the retina and reduced stroke 
volume in the brain. Our observations were further con-
firmed by loss-of-function assays, because CSF injection of a 
neutralizing  antibody  against  mouse  PDGF-CC  enlarged 
stroke volume. In summary, using both genetic and pharma-
cological tools, our data showed that PDGF-CC has a negli-
gible role in inducing blood vessel permeability while having 
a potent neuroprotective effect. On the other hand, it is 
known that differences in the degree and timing of PDGFR 
activation can lead to different biological effects. Thus, we 
cannot exclude the possibility that the difference between 
our results and the previous ones (Su et al., 2008) on the role 
of PDGF-CC in inducing blood vessel permeability may re-
late to different controls used, experimental conditions, ani-
mal models, or proteins used. Further studies are needed to 
verify this.
Our previous work showed that PDGF-CC at a relatively 
high dose (4.5 µg/mouse/day for 7 d) promoted angiogenesis 
in  pathological  conditions  in  the  heart  (Dimmeler,  2005;   
Li et al., 2005). There is therefore a possibility that the neuro-
protective effect of PDGF-CC could be an indirect effect via 
its vascular effect by improving blood supply. In this study, 
using an acute neural toxin NMDA-induced retinal neuron 
injury model in which only neurons were injured and the 
vascular system was not affected, and in which PDGF-CC 
treatment lasted only for 24 h (a time period too short for new 
blood vessels to grow), PDGF-CC treatment rescued retinal 
neurons from apoptosis, suggesting a direct neuroprotective 
effect of PDGF-CC on neurons. This notion was further 
supported by neuronal culture experiments in which PDGF-CC 
treatment rescued cultured primary neurons from apoptosis 
when the neurons were challenged by hypoxia, glucose/se-
rum deprivation, or neurotoxin injury. In addition, although 
genome-wide gene profiling revealed a regulatory effect of 
PDGF-CC  on  the  expression  of  numerous  apoptotic/cell 
death–related and survival/neurotrophic genes, it did not sig-
nificantly affect the expression profile of angiogenic/proan-
giogenic genes (unpublished data). Thus, PDGF-CC at a dose 
effective for neuroprotection did not induce angiogenesis in 
the brain or retina.JEM VOL. 207, April 12, 2010 
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(Sigma-Aldrich) in artificial CSF (124 mM NaCl, 5 mM KCl, 3.2 mM 
MgCl2, 0.1 mM CaCl2, 26 mM NaHCO3, and 10 mM D-glucose) for 20 min 
and washed with culture medium (1:1 of DMEM/F12, supplemented with 
10% FBS and 100 U/ml penicillin/streptomycin; Invitrogen). The cells were 
plated  into  polyornithine-coated  dishes  at  5  ×  105  cells/cm2.  After  3  h,   
medium was changed to Neurobasal A with or without B27 (Invitrogen). The 
neural progenitor cells were cultured in serum-free medium with or without 
50 ng/ml of PDGF-CC protein for 7 d and subjected to anti-TH or TUNEL 
staining. Or, the SN-derived cells were treated with 30 or 100 µM 6-OHDA 
for 24 h and subjected to anti-TH staining. Images were taken from eight   
randomly selected microscopic fields and TH+ cells were counted. All of the 
experiments were performed in triplicate and were repeated at least once.
Real-time PCR, in situ hybridization, and immunofluorescent and 
TUNEL staining. For real-time PCR assay, total RNA was isolated using 
the RNeasy Mini kit according to the manufacturer’s instructions. 3 µg of 
total RNA was used for cDNA synthesis using the SuperMix kit (Invitrogen) 
and was used for the real-time PCR reaction using a sequence detection   
system (ABI Prism 7500 HT; Applied Biosystems). All experiments were 
performed in triplicate and repeated at least once. Primers used are listed in 
Table  S1.  Immunofluorescent  staining  and  in  situ  hybridization  were   
performed as previously described (Li et al., 2000). TUNEL assay was per-
formed according to the manufacturer’s protocol (Roche). Antibodies used 
for immunofluorescent staining were anti-islet1 (clone 39.4D5; Develop-
mental  Studies  Hybridoma),  anti-TH,  anti–phosphorylated  PDGFR- 
(Santa Cruz Biotechnology, Inc.), anti–phosphorylated PDGFR- (Santa 
Cruz Biotechnology, Inc.), rabbit anti–mouse collagen IV polyclonal anti-
body (AbD Serotec), and anti–PDGF-CC (Li et al., 2000). For in situ hybrid-
ization, a mouse PDGF-C antisense riboprobe and 12-µm frozen tissue sections 
were used. A sense riboprobe was used as a negative control. The riboprobes 
were prepared using T7 and T3 RNA polymerases and digoxigenin-11-dUTP 
(Roche) according to the manufacturer’s instructions.
PDGFR-,  PDGFR-,  and  Akt  activation/expression  assay  and 
Western blotting. PDGFR and Akt activation assays were performed as 
previously described (Li et al., 2000). In brief, for in vitro receptor and Akt 
activation assays, cultured cells were stimulated with the active form of rhP-
DGF-CC protein (Li et al., 2000) at 50 ng/ml for 10 min and cell lysate was 
subjected to further analysis. For in vivo receptor activation assays, PDGF-
CC protein was injected into mouse vitreous or SN (500 ng/µl × 1 µl), and 
tissues were harvested after 20 min to 2 h for receptor activation assay. For 
immunoprecipitation assay, cell lysates were incubated with anti–PDGFR- 
(Santa Cruz Biotechnology, Inc.) or anti–PDGFR- antibody (Santa Cruz 
Biotechnology, Inc.) overnight at 4°C and were precipitated with immobi-
lized  protein  G  (Thermo  Fisher  Scientific).  Immunoprecipitated  samples 
were separated by 10% SDS-PAGE and transferred to a polyvinylidene fluo-
ride membrane and were incubated with an antiphosphotyrosine antibody 
(PY99; Santa Cruz Biotechnology, Inc.). Other antibodies used for Western 
blot assays were anti–mouse PDGF-CC (R&D Systems), anti-TH, and mono-
clonal anti–-actin conjugated with horseradish peroxidase (Sigma-Aldrich).
Phospho-MAPK antibody array screening and GSK3 phosphoryla-
tion and expression assays. For phospho-MAPK antibody array screening, 
HUVSMCs were cultured as instructed (American Type Culture Collection), 
serum starved overnight, and treated with 50 ng/ml of the active form of rh-
PDGF-CC protein for 10 min. The cells were then processed for the human 
phospho-MAPK array assay according to the manufacturer’s protocol (R&D 
Systems). The processed array membrane was scanned and quantified using an 
image reader (LAS-3000) and Multi Gauge software (Fujifilm). For in vivo 
GSK3  phosphorylation  assay,  500  ng/ml  of  rhPDGF-CC  protein  was   
injected into mouse vitreous, and the retinae were harvested after 1–24 h for 
Western blot assay. The GSK3-WT and GSK3-A9 expression constructs 
were a gift from J.S. Gutkind (National Institute of Dental and Craniofacial 
Research, NIH, Bethesda, MD). Antibodies used for Western blotting were 
anti-GSK3/  (R&D  Systems),  anti–phospho-GSK3/  (S21/S9;  R&D 
Systems), and anti–phospho-GSK3/ (Tyr279/Tyr216; Millipore).
6-OHDA  injection)  and  subjected  to  subsequent  analysis.  TH  staining   
using a commercial anti-TH antibody (Abcam) in both SN and ST was   
visualized using AxioVision software (Carl Zeiss, Inc.).
Cerebral ischemic stroke model. Focal cerebral ischemia was produced by 
permanent MCAO as described previously (Li et al., 2008). For PDGF-CC 
protein treatment, 3 µl of 3 µM active rhPDGF-CC protein or the same 
amount of BSA in PBS was injected into CSF. For PDGF-CC neutralizing 
antibody treatment, 3 µl of 0.4 µg/µl of neutralizing antibody against mouse 
PDGF-CC or the same amount of IgG in PBS was injected into CSF. 1 h after 
protein or neutralizing antibody injection, MCAO was performed and stroke 
volume was measured 24 h after MCAO. For PDGF-CC protein injection 
into cortex, a skin incision was made at the top of the head of the anesthetized 
mouse. Three small openings (1 mm in diameter) were made in the skull at 
1, 0, and 1 mm from the bregma to the lambda and 1 mm left from bregma. 
A fine needle (33 gauge) was inserted to a depth of 1.2 mm from the skull sur-
face, and 0.3 µg of rhPDGF-CC core domain protein (Li et al., 2000) or BSA 
in 0.5 µl PBS was injected over 5 min into each opening and the skin was su-
tured. 1 wk after PDGF-CC protein injection, MCAO was performed and 
stroke volume was measured 24 h after MCAO. We chose to inject the PDGF-
CC protein 7 d before MCAO because it allowed us to compare the neuro-
protective effect of PDGF-CC with that of PDGF-BB, which was shown to 
be effective when administered 7 d before MCAO (Sakata et al., 1998).
Microarray analysis. 7 d after the ONC injury and PDGF-CC protein 
treatment,  retinae  were  harvested  and  total  RNA  was  isolated  using 
TRIzol reagent (Invitrogen) followed by RNeasy Mini kit (QIAGEN) 
purification according to the manufacturer’s instructions. Microarray assay 
was  performed  using  Mouse-6  Expression  BeadChips  (Illumina  Inc.)   
containing 48,000 mouse transcripts. Three biological repeats were in-
cluded in the microarray assay. A two-tailed Student’s t test was used for 
statistical analysis of gene expression data. Functional grouping of the dif-
ferentially  expressed  genes  was  performed  using  several  different  tools,   
including the WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt) and 
the Ingenuity Pathways Analysis (https://analysis.ingenuity.com/pa/login/
login.jsp)  programs.  Microarray  data  have  been  deposited  in  the  Gene   
Expression Omnibus under accession no. GSE19207.
Cell culture, isolation of primary neurons from brain and retina, 
and survival assay. Rat RGC-derived cell line RGC5 cells were cultured 
in DMEM containing 10% FBS and 1% penicillin/streptomycin at 37°C 
with 5% CO2. For cell survival/viability assay, RGC5 cells were starved in 
serum-free medium for 3 d. Cells were seeded in a 96-well tissue culture 
plate (BD) and allowed to attach for 24 h in serum-free medium. The me-
dium was replaced with 100 µl of serum-free medium supplemented with 
50 ng/ml of rhPDGF-CC core domain protein (Li et al., 2000). Serum-free 
medium with 50 ng/ml BSA was used as a negative control. Cell-culture 
medium with 10% FBS was used as a positive control. Cell viability was 
evaluated using the methylthiazolyldiphenyl-tetrazolium bromide method 
according  to  the  manufacturer’s  protocol  (Invitrogen)  at  different  time 
points. Or, RGC5 cells were stressed with 2.5 mM H2O2 for 1 h with or 
without 50 ng/ml of PDGF-CC protein treatment. Apoptosis was investi-
gated after 24 h using terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay. Cortical neurons were isolated from 1-d-old neo-
natal mice as previously described (Li et al., 2008) and collected into Neu-
robasal A media (Invitrogen) with 0.1% EDTA and digested with trypsin 
(Invitrogen) for 30 min at 37°C, followed by density gradient centrifugation 
with 7, 9.4, 11.9, and 16.4% Optiprep (Axis-Shield). Neurons positioned 
between the second and third layers were collected and cultured in Neuro-
basal A for subsequent analysis. Neuronal survival experiments were per-
formed within 10 d of culture. For neuronal survival assay, neurons were 
cultured in serum-free medium without glucose in 1% oxygen at 37C° for 
6 h. TUNEL assay was performed as previously described (Li et al., 2008).
Neural cells from SN and retina were isolated from E13.5 and P3 mice, 
respectively. Tissues were treated with 12 U/ml papain with 2 U/ml DNase I 880 PDGF-CC protects neurons | Tang et al.
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treatment decreased PDGF-C expression level in the SN (A), PDGF-C gene 
delivery into SN led to PDGF-C overexpression (B), PDGF-CC protein 
SN injection did not change blood vessel permeability (C), and immuno-
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the retinae (F–H). Online supplemental material is available at http://www 
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